Corona Remedies Ltd

- CORONA Remedies is investing in a new hormonal manufacturing plant in Ahmedabad, which has received the state Schedule M license and is expected to commence commercial production by Q2-end or early Q3 of FY '27. - The company aims to obtain WHO and EU GMP certifications for this plant by the end of FY '27 to ramp up its international hormonal products business. - There is a significant solar power investment: an existing 1.3 MW solar plant at Bhayla and a planned 4.25 MW solar park covering 11.9 acres, aimed at reducing electricity costs and supporting ESG initiatives. - CORONA is actively evaluating inorganic growth opportunities via M&A and in-licensing but remains selective, focusing on strategic fit and brand alignment rather than solely company origin. - The focus is on expanding marketing and field force by 5-7% annually to support growth and new therapy launches, indirectly requiring investment in human capital.

- CORONA Remedies aims for **15% compound annual growth rate (CAGR) in revenue** over the next 3 to 4 years. - The target for **profit after tax (PAT) or earnings per share (EPS) growth is around 20% year-on-year** for the next 3 to 4 years. - Revenue growth is generally steady with minor seasonal variations; Q3 sees slightly less growth due to festive season. - The company plans to expand its sales force by **5-7% annually**, supporting growth and new therapy launches. - Expansion into new therapies like infertility, spine, rheumatoid, CNS, dermatology, and gastrointestinal is expected to drive additional growth. - International business is in early stages but aims to contribute with hormonal products post plant commissioning, targeting higher single-digit contribution in a couple of years.

- CORONA Remedies targets a **15% CAGR revenue growth** over the next 3 to 4 years. - The company aims for **20% PAT (Profit After Tax) or EPS (Earnings Per Share) growth** annually over the same period. - Management's endeavor is to sustain about **22%-23% margin bank** for FY '27 with potential reinvestment in marketing or field force. - The firm's plan includes a consistent expansion of medical representatives by **5%-7% annually** to support growth. - The new hormonal product plant is expected to contribute to international revenues starting FY '28, helping boost overall growth. - Profitability improvements are steady, with PAT margin fluctuations around 100 basis points quarter-on-quarter historically. - The focus on chronic therapies and specialist segments supports enhanced margins and sustainable profit growth.

The provided transcript and document pages do not mention any details regarding the current or expected order book or pending orders for CORONA Remedies Limited. The discussion mainly covers financial performance, growth strategies, acquisitions, marketing approach, product portfolio, manufacturing capabilities, and future outlook, but no specific information about order books or pending orders is disclosed.

- The transcript does not mention any current or planned fundraising through equity. - There is no explicit discussion about raising debt in the call. - Focus appears to be on organic growth and limited acquisitions (small acquisition from Bayer-Zydus done recently around INR 7.5-8 crores). - Plans include expanding manufacturing capacity, launching new therapies, and increasing marketing force funded through internal accruals. - No direct indication of external fundraising through either debt or equity in the immediate or near future.